Search

Displaying results 7021 - 7030 of 8696 in total
  1. Drug

    Carbon black

    go.drugbank.com/drugs/DB11980
    Investigational

    Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function. … [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416]

  2. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Livmoniplimab

    go.drugbank.com/drugs/DB18939
    Investigational

    With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)). … Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination

  4. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.

  5. Drug

    CTX130

    go.drugbank.com/drugs/DB18627
    Investigational

    CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

  6. Drug

    Piromidic acid

    go.drugbank.com/drugs/DB13744
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Tribenoside

    go.drugbank.com/drugs/DB13227
    Investigational

    Anti-inflammatory agent used in edema of extremities, varicose veins & phlebitis.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  8. Drug

    Vafidemstat

    go.drugbank.com/drugs/DB16446
    Investigational

    Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).

  9. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB21765
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen

    go.drugbank.com/drugs/DB17995
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen